亚太药业：协议转让股份完成过户，邱中勋为公司新实控人

Core Viewpoint - The control change at Asia-Pacific Pharmaceutical (亚太药业) has been completed, with Xinghao Holdings becoming the new controlling shareholder, holding a total of 14.61% voting rights, marking a significant transition in the company's leadership and strategic direction [1][2] Group 1: Control Change Details - Xinghao Holdings acquired 14.61% of the voting rights through a combination of direct shareholding and the transfer of voting rights from a related party [1] - The share transfer involved a total transaction amount of 900 million yuan at a price of 8.26 yuan per share, representing a premium of 45.68% over the pre-suspension price of 5.67 yuan per share [1] Group 2: Future Plans and Strategic Direction - Following the share issuance, Xinghao Holdings is expected to hold 22.38% of the company's shares, further solidifying its control [2] - The new actual controller, Qiu Zhongxun, is a prominent figure in the pharmaceutical industry, which is anticipated to enhance the company's innovation and development capabilities [2] - Asia-Pacific Pharmaceutical plans to transition from traditional chemical generics to improved new drugs and innovative drug development, supported by a fundraising effort of up to 700 million yuan for research projects [1][2]